相似文献
1
Critically Ill Patient with Multidrug-Resistant Acinetobacter baumannii Respiratory Infection Successfully Treated with Intravenous and Nebulized Bacteriophage Therapy.
Antimicrob Agents Chemother. 2022 Jan 18;66(1):e0082421. doi: 10.1128/AAC.00824-21. Epub 2021 Oct 18.
2
Multidrug resistant Acinetobacter baumannii: a descriptive study in a city hospital.
BMC Infect Dis. 2010 Jul 7;10:196. doi: 10.1186/1471-2334-10-196.
3
An increasing threat in hospitals: multidrug-resistant Acinetobacter baumannii.
Nat Rev Microbiol. 2007 Dec;5(12):939-51. doi: 10.1038/nrmicro1789.
4
[Nebulized colistin treatment of multi-resistant Acinetobacter baumannii pulmonary infection in critical ill patients].
Med Intensiva. 2011 May;35(4):226-31. doi: 10.1016/j.medin.2011.01.013. Epub 2011 Mar 10.
5
Specific and Selective Bacteriophages in the Fight against Multidrug-resistant Acinetobacter baumannii.
Virol Sin. 2019 Aug;34(4):347-357. doi: 10.1007/s12250-019-00125-0. Epub 2019 May 15.
6
Multidrug resistant and extensively drug resistant Acinetobacter baumannii hospital infection associated with high mortality: a retrospective study in the pediatric intensive care unit.
BMC Infect Dis. 2020 Aug 12;20(1):597. doi: 10.1186/s12879-020-05321-y.
7
Outcomes of Acinetobacter baumannii infection in critically ill surgical patients.
Surg Infect (Larchmt). 2007 Aug;8(4):437-43. doi: 10.1089/sur.2006.029.
8
Confronting multidrug-resistant Acinetobacter baumannii: a review.
Int J Antimicrob Agents. 2011 Feb;37(2):102-9. doi: 10.1016/j.ijantimicag.2010.10.014. Epub 2010 Dec 4.
9
Ability of bacteriophage in resolving wound infection caused by multidrug-resistant Acinetobacter baumannii in uncontrolled diabetic rats.
Microb Drug Resist. 2015 Apr;21(2):171-7. doi: 10.1089/mdr.2014.0120. Epub 2014 Nov 20.
10
The Use of Intravenous and Inhaled Colistin Therapy During a Burn Center Outbreak of Multidrug-Resistant Acinetobacter baumannii.
J Burn Care Res. 2018 Oct 23;39(6):1029-1036. doi: 10.1097/BCR.0000000000000626.
引用本文的文献
1
Antibiotic-resistant Acinetobacter baumannii can be killed by a combination of bacteriophages and complement.
Med Microbiol Immunol. 2025 Sep 2;214(1):40. doi: 10.1007/s00430-025-00852-0.
2
Bacteriophages as an alternative strategy for the treatment of drug resistant bacterial infections: Current approaches and future perspectives.
Cell Surf. 2025 Jul 3;14:100149. doi: 10.1016/j.tcsw.2025.100149. eCollection 2025 Dec.
3
The Current Landscape of Phage-Antibiotic Synergistic (PAS) Interactions.
Antibiotics (Basel). 2025 May 27;14(6):545. doi: 10.3390/antibiotics14060545.
4
The intricacies of : a multifaceted comprehensive review of a multidrug-resistant pathogen and its clinical significance and implications.
Front Microbiol. 2025 May 12;16:1565965. doi: 10.3389/fmicb.2025.1565965. eCollection 2025.
5
[Potential of bacteriophage therapy in Germany: evidence and clinical relevance].
Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz. 2025 Apr 28. doi: 10.1007/s00103-025-04048-y.
6
Antibiotic Use in Livestock Farming: A Driver of Multidrug Resistance?
Microorganisms. 2025 Mar 28;13(4):779. doi: 10.3390/microorganisms13040779.
7
Re-Emergence of Bacteriophages and Their Products as Antibacterial Agents: An Overview.
Int J Mol Sci. 2025 Feb 19;26(4):1755. doi: 10.3390/ijms26041755.
8
Phage therapy in the management of respiratory and pulmonary infections: a systematic review.
Ther Adv Infect Dis. 2025 Jan 24;12:20499361241307841. doi: 10.1177/20499361241307841. eCollection 2025 Jan-Dec.
9
Phage therapy for extensively drug resistant infection: case report and evaluation of the distribution of phage and the impact on gut microbiome.
Front Med (Lausanne). 2024 Dec 20;11:1432703. doi: 10.3389/fmed.2024.1432703. eCollection 2024.
10
Characterization of phage HZY2308 against Acinetobacter baumannii and identification of phage-resistant bacteria.
Virol J. 2024 Nov 7;21(1):283. doi: 10.1186/s12985-024-02556-y.
本文引用的文献
1
Bacteriophage Therapy of Bacterial Infections: The Rediscovered Frontier.
Pharmaceuticals (Basel). 2021 Jan 5;14(1):34. doi: 10.3390/ph14010034.
2
Bacteriophage-resistant Acinetobacter baumannii are resensitized to antimicrobials.
Nat Microbiol. 2021 Feb;6(2):157-161. doi: 10.1038/s41564-020-00830-7. Epub 2021 Jan 11.
3
Salvage Bacteriophage Therapy for a Chronic MRSA Prosthetic Joint Infection.
Antibiotics (Basel). 2020 May 9;9(5):241. doi: 10.3390/antibiotics9050241.
4
Specific and Selective Bacteriophages in the Fight against Multidrug-resistant Acinetobacter baumannii.
Virol Sin. 2019 Aug;34(4):347-357. doi: 10.1007/s12250-019-00125-0. Epub 2019 May 15.
5
Successful Treatment of Antibiotic-resistant, Poly-microbial Bone Infection With Bacteriophages and Antibiotics Combination.
Clin Infect Dis. 2019 Nov 13;69(11):2015-2018. doi: 10.1093/cid/ciz222.
6
Phage therapy for respiratory infections.
Adv Drug Deliv Rev. 2018 Aug;133:76-86. doi: 10.1016/j.addr.2018.08.001. Epub 2018 Aug 7.
7
The history and promising future of phage therapy in the military service.
J Trauma Acute Care Surg. 2018 Jul;85(1S Suppl 2):S18-S26. doi: 10.1097/TA.0000000000001809.
8
Development and Use of Personalized Bacteriophage-Based Therapeutic Cocktails To Treat a Patient with a Disseminated Resistant Acinetobacter baumannii Infection.
Antimicrob Agents Chemother. 2017 Sep 22;61(10). doi: 10.1128/AAC.00954-17. Print 2017 Oct.
9
Prognostic factors associated with mortality of drug-resistant Acinetobacter baumannii ventilator-associated pneumonia.
J Intensive Care. 2015 Mar 2;3:9. doi: 10.1186/s40560-015-0077-4. eCollection 2015.
10
Development of a high throughput assay for indirectly measuring phage growth using the OmniLog(TM) system.
Bacteriophage. 2012 Jul 1;2(3):159-167. doi: 10.4161/bact.21440.
Zotero 插件